sb 239063 has been researched along with Eosinophilia in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Eosinophilia: Abnormal increase of EOSINOPHILS in the blood, tissues or organs.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Underwood, DC | 1 |
| Osborn, RR | 1 |
| Kotzer, CJ | 1 |
| Adams, JL | 1 |
| Lee, JC | 1 |
| Webb, EF | 1 |
| Carpenter, DC | 1 |
| Bochnowicz, S | 1 |
| Thomas, HC | 1 |
| Hay, DW | 1 |
| Griswold, DE | 1 |
1 other study available for sb 239063 and Eosinophilia
| Article | Year |
|---|---|
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Topics: Administration, Inhalation; Animals; Apoptosis; Blotting, Western; Bronchoalveolar Lavage Fluid; Bro | 2000 |